[1]
(a)Hewawasam, P.; Meanwell, N.A.; Gribkoff, V.K. 3-Substituted
oxindole derivatives as potassium channel modulators U.S. Patent
5,565,483, October 15, 1996;.
(b)Hewawasam, P.; Meanwell, N. A.; Gribkoff, V.K. 3-Substituted oxindole derivatives as potassium
channel modulators. US. Patent 5,602,169A, February 11, 1997.
[3]
Hewawasam, P.; Gribkoff, V.K.; Dworetzky, S.I.; Ortiz, A.A.; Kinney, G.G.; Boissard, C.G.; Post-Munson, D.J.; Trojnacki, J.T.; Huston, K.; Signor, L.G.; Lombardo, L.A.; Reid, S.A.; Hibbard, J. R.; Myers, R.A.; Moon, S.L.; Wiener, H.L.; Thalody, G.; Yeleswaram, K.; Pajor, L.M.; Knipe, J.O.; Meanwell, N.A.; Johnson, G.; Molinoff, P.B.; Starrett, J.E., Jr; Gao, Q. Discovery of openers of
large conductance, calcium activated potassium (maxi-K) channels:
A new approach to stroke neuroprotection. Abstr. Pap. Am. Chem.
S, 2000, 219, 320-MEDI, Part, 2.
[18]
Frantz, S.W.; Srinivas, N.; Dominick, M.; Kelly, W.; Sanderson, T.; Schilling, B. Safety assessment of BMS-204352, a novel therapeutic agent for the treatment of stroke. Eur. J. Neurol., 2000, 7(Suppl. 3), 3017.